NOVO.B.DK

414

-2.79%↓

COLO.B.DK

607.4

+0.16%↑

GMAB.DK

1,419

-0.14%↓

HLUNB.DK

33.72

-1.29%↓

AMBUB.DK

98.55

-0.86%↓

NOVO.B.DK

414

-2.79%↓

COLO.B.DK

607.4

+0.16%↑

GMAB.DK

1,419

-0.14%↓

HLUNB.DK

33.72

-1.29%↓

AMBUB.DK

98.55

-0.86%↓

NOVO.B.DK

414

-2.79%↓

COLO.B.DK

607.4

+0.16%↑

GMAB.DK

1,419

-0.14%↓

HLUNB.DK

33.72

-1.29%↓

AMBUB.DK

98.55

-0.86%↓

NOVO.B.DK

414

-2.79%↓

COLO.B.DK

607.4

+0.16%↑

GMAB.DK

1,419

-0.14%↓

HLUNB.DK

33.72

-1.29%↓

AMBUB.DK

98.55

-0.86%↓

NOVO.B.DK

414

-2.79%↓

COLO.B.DK

607.4

+0.16%↑

GMAB.DK

1,419

-0.14%↓

HLUNB.DK

33.72

-1.29%↓

AMBUB.DK

98.55

-0.86%↓

Search

Zealand Pharma A-S

Closed

361.9 0.58

Overview

Share price change

24h

Current

Min

359.8

Max

369.8

Key metrics

By Trading Economics

Income

-44M

-335M

Sales

-964K

8.1M

EPS

-4.75

Profit margin

-4,144.13

Employees

385

EBITDA

-253M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

+25.15% upside

Dividends

By Dow Jones

Next Earnings

14 sie 2025

Market Stats

By TradingEconomics

Market Cap

-4.4B

26B

Previous open

361.32

Previous close

361.9

Zealand Pharma A-S Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 mar 2025, 09:23 UTC

Major Market Movers

Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche

20 gru 2024, 09:22 UTC

Major Market Movers

Zealand Pharma Shares Fall After FDA Pushes Back Bowel-Disease Drug

12 mar 2025, 16:34 UTC

Top News

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal -- Update

12 mar 2025, 08:18 UTC

Market Talk

Roche's Obesity Deal With Zealand Pharma Makes Sense, Vontobel Says -- Market Talk

Peer Comparison

Price change

Zealand Pharma A-S Forecast

Price Target

By TipRanks

25.15% upside

12 Months Forecast

Average 270.582 DKK  25.15%

High 270.568 DKK

Low 270.568 DKK

Based on 1 Wall Street analysts offering 12 month price targets forZealand Pharma A-S - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Zealand Pharma A-S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.